Key Highlights

  • Shares fell 1.21% to USD 122.52 on relative Volume of 1.93.
  • Third-quarter Revenue was USD 274.4 million, with Net Income of USD 220.0 million.
  • The board authorized a share repurchase of up to USD 300.0 million.
  • MIMRYLO approval triggered a USD 200.0 million payment and a USD 75.0 million milestone.

Protagonist Therapeutics (NASDAQ:PTGX) shares traded at USD 122.52 on November 20, 2026, down 1.21%, with a relative volume at time of 1.93. The company has given no reason for the heavy trading. It announced a share repurchase program on September 8 and filed its Quarterly Report on November 6, so those events predate the session.

Protagonist is a Delaware corporation based in Newark, California. It is a biopharmaceutical company built on a proprietary peptide technology platform, with programs in inflammation and immunology, hematology and metabolic diseases. It has license and collaboration agreements with Johnson & Johnson for oral IL-23R antagonist candidates, including ICOTYDE, and with Takeda for MIMRYLO.

Share Repurchase Program

On September 8 the board authorized repurchases of up to USD 300.0 million of common stock. The program has no fixed expiration, carries no obligation to buy any set number of shares and can be modified, suspended or ended at any time.

The Third Quarter

License and collaboration revenue was USD 274.4 million versus USD 4.7 million. Research and Development expense was USD 41.3 million versus USD 40.0 million, and general and administrative expense was USD 13.7 million versus USD 11.1 million.

Income from operations was USD 218.3 million versus a loss of USD 46.4 million. Income tax expense was USD 6.6 million. Net income was USD 220.0 million versus a net loss of USD 39.3 million. Basic net income per share was USD 3.32, and diluted net income per share was USD 3.07 versus a net loss per share of USD 0.62.

Nine Months

License and collaboration revenue was USD 544.3 million versus USD 38.6 million. Income from operations was USD 373.5 million versus a loss of USD 107.8 million. Net income was USD 386.6 million versus a net loss of USD 85.8 million, with basic net income per share of USD 5.88 and diluted net income per share of USD 5.43 versus a loss of USD 1.35.

Collaboration Agreements

Under the Johnson & Johnson agreement, the company earned a USD 50.0 million milestone in the first quarter when the FDA approved ICOTYDE for moderate-to-severe plaque psoriasis. Since 2017 it has earned USD 387.5 million in upfront and milestone payments, and it is eligible for tiered royalties of 6% to 10% on net product sales and sales milestones of up to USD 425.0 million.

Under the Takeda agreement, the company said on April 28 that it exercised its right to opt out of the U.S. profit and loss sharing arrangement, which triggered a USD 200.0 million payment. The FDA approval of MIMRYLO in August brought another USD 200.0 million opt-out payment and a separate USD 75.0 million milestone. The company can receive up to USD 800.0 million in development and sales milestones for polycythemia vera and tiered royalties of 14% to 29% on annual worldwide net sales. The open-label extension is expected to finish in the first quarter of 2027.

Balance Sheet

Cash was USD 498.3 million versus USD 128.4 million at December 31, 2025, and current marketable securities were USD 301.8 million versus USD 439.0 million. Total Assets were USD 1.15 billion versus USD 668.2 million, liabilities were USD 61.6 million and Equity was USD 1.08 billion versus USD 614.7 million.

What to Watch Next for Protagonist

The company has given no reason for the November 20 trading, and its results, approvals and buyback came earlier. The reported record shows a swing from loss to profit on milestone revenue and a much larger cash position. The MIMRYLO extension study in the first quarter of 2027 is the next dated item.